Back to Search
Start Over
Development of PMMA membranes functionalized with hydroxypropyl-β-cyclodextrins for controlled drug delivery using a supercritical CO2-assisted technology
- Source :
- International Journal of Pharmaceutics. 376:110-115
- Publication Year :
- 2009
- Publisher :
- Elsevier BV, 2009.
-
Abstract
- Cyclodextrin-containing polymers have proved themselves to be useful for controlled release. Herein we describe the preparation of membranes of poly(methylmethacrylate) (PMMA) containing hydroxypropyl-beta-cyclodextrins (HP-beta-CDs) using a supercritical CO(2)-assisted phase inversion method, for potential application as drug delivery devices. Results are reported on the membrane preparation, physical properties, and drug elution profile of a model drug. The polymeric membranes were obtained with HP-beta-CD contents ranging from 0 to 33.4 wt%, by changing the composition of the casting solution, and were further impregnated with ibuprofen using supercritical carbon dioxide (scCO(2)) in batch mode. The influence of the membrane functionalization in the controlled release of ibuprofen was studied by performing in vitro experiments in buffer solution pH at 7.4. The release of the anti-inflammatory drug could be tuned by varying the cyclodextrin content on the membranes.
- Subjects :
- chemistry.chemical_classification
Materials science
Supercritical carbon dioxide
Chromatography
Cyclodextrin
beta-Cyclodextrins
Pharmaceutical Science
Green Chemistry Technology
Ibuprofen
Membranes, Artificial
Carbon Dioxide
In Vitro Techniques
Controlled release
Phase Transition
Supercritical fluid
Dosage form
2-Hydroxypropyl-beta-cyclodextrin
Drug Delivery Systems
Membrane
chemistry
Chemical engineering
Delayed-Action Preparations
Drug delivery
Polymethyl Methacrylate
Phase inversion (chemistry)
Subjects
Details
- ISSN :
- 03785173
- Volume :
- 376
- Database :
- OpenAIRE
- Journal :
- International Journal of Pharmaceutics
- Accession number :
- edsair.doi.dedup.....13ca76d11ccc1e9938fe1634dba61e69
- Full Text :
- https://doi.org/10.1016/j.ijpharm.2009.04.029